Structural pharmacogenomics, drug resistance and the design of anti-infective super-drugs

Drug Discovery Today

Volumn 7, Issue 24, 2002, Pages 1214-1220

  Maggio, Edward T ^a   Shenderovich, Mark ^a   Kagan, Ron ^b   Goddette, Dean ^a   Ramnarayan, Kal ^a  

^a Structural Bioinformatics Inc   (United States)

^b QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIINFECTIVE AGENT; INDINAVIR; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE; RITONAVIR; SAQUINAVIR; TIPRANAVIR;

CLINICAL TRIAL; COMPARATIVE STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG SCREENING; DRUG TARGETING; GENETIC POLYMORPHISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHARMACOGENOMICS; POPULATION; PROTEIN ANALYSIS; REVIEW; VIRUS REPLICATION;

ANIMALS; ANTI-HIV AGENTS; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE, VIRAL; HUMANS; MODELS, CHEMICAL; MODELS, MOLECULAR; PHARMACOGENETICS;

EID: 0037115020     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(02)02514-X     Document Type: Review

References (14)

1. Shafer R.W., et al. The genetic basis of HIV-1 reverse transcriptase and protease inhibitors. AIDS Rev. 2:2000;211-228.
2. Richman D.D. HIV chemotherapy. Nature. 410:2001;995-1001.
3. Perno C.F., et al. Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. J. Infect. Dis. 184:2001;983-991.
4. Wang W., Kollman P.A. Computational study of protein specificity: the molecular basis of HIV-1 protease drug resistance. Proc. Natl. Acad. Sci. U. S. A. 98:2001;14937-14942.
5. Harrigan P.R., et al. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS. 15:2001;1671-1677.
6. Maggio E.T., Ramnarayan K. Recent developments in computational proteomics. Drug Discov. Today. 6:2001;996-1004.
7. Boulme R., et al. Comparative evaluation between five automated resistance interpretation algorithms. Antivir. Ther. 6:(Suppl. 1):2001;121.
8. Larder B.A., et al. Quantitative prediction of HIV-1 phenotypic drug resistance from genotypes: the virtual phenotype (VirtualPhenotype). Antivir. Ther. 5:(Suppl. 3):2000;49.
9. Shenderovich, M. et al. (2002) Structural Phenotype Predicts HIV-1 Protease Inhibitor Resistance. Presented at the 9th Conference on Retroviruses and Opportunistic Infections, 24-28 February 2002.
10. Shenderovich M., et al. Structural pharmacogenomic approach to the evaluation of drug resistant mutations in HIV-1 protease. J. Clin. Ligand Assay. 24:2001;140-144.
11. Qari S.H., et al. Comparative analysis of two commercial phenotypic assays for drug susceptibility testing of human immunodeficiency virus type 1. J. Clin. Microbiol. 40:2002;31-35.
12. Petropoulos C.J., et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44:2000;920-928.
13. Dam E., et al. Comparison of HIV-1 resistance phenotypes obtained by two different assay systems. Antiviral Ther. 6:(Suppl. 1):2001;122.
14. Hong L., et al. Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance. Protein Sci. 9:2000;1898-1904.